Efficacy of Low Dose Sugammadex in Reversal of NMB in Laparoscopic Barbaric Surgery
NCT ID: NCT02713113
Last Updated: 2016-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
180 participants
INTERVENTIONAL
2015-03-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.
NCT03381209
Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery
NCT01631396
Sugammadex on Laparoscopic Bariatric Surgery
NCT06678451
Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions
NCT02118844
Ketamine Infusion vs Dexmedetomidine Infusion in Obese Patients Undergoing Bariatric Surgery
NCT04576975
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group I: patients were given 1.5 mg / kg. Group II: patients were given 2 mg / kg. Group III: patients were given 4 mg / kg.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
sugammadex reversal of neuromuscular blockade
group II
patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
sugammadex reversal of neuromuscular blockade
group III
patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
sugammadex reversal of neuromuscular blockade
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sugammadex reversal of neuromuscular blockade
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* scheduled for elective laparoscopic bariatric surgery (gastric bypass or sleeve surgery) under general anesthesia using rocuronium for tracheal intubation and maintenance of NMB
* aged between 18 and 60 years and classified as ASA II - III
Exclusion Criteria
* disabling neuropsychiatric disorders,
* history of stroke, brain trauma in the last 12 months
* hypersensitivity to anesthetics, history of myocardial infarction, congestive heart failure
* difficult tracheal intubation, and known or suspected disorder affecting NMB.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fatma Adel El sherif
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed H Othman, MD
Role: STUDY_DIRECTOR
ASSUIT UNVERSITY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Egypt Cancer Instuite
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
250
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.